deferoxamine has been researched along with Coronary Disease in 24 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Coronary Disease: An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Salicylic acid was used as the probe for ." | 1.28 | Quantification of hydroxyl radical and its lack of relevance to myocardial injury during early reperfusion after graded ischemia in rat hearts. ( Ashraf, M; Onodera, T; Takemura, G, 1992) |
| "Deferoxamine pretreatment also decreased (P less than ." | 1.28 | Deferoxamine pretreatment reduces canine infarct size and oxidative injury. ( Horwitz, LD; Lesnefsky, EJ; Repine, JE, 1990) |
| "Deferoxamine-treated hearts recovered 99 +/- 10% of control PCr content, while untreated hearts recovered 60 +/- 16% (p less than ." | 1.27 | Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury. ( Ambrosio, G; Flaherty, JT; Jacobus, WE; Weisfeldt, ML; Zweier, JL, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 14 (58.33) | 18.7374 |
| 1990's | 8 (33.33) | 18.2507 |
| 2000's | 2 (8.33) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Patterson, E | 1 |
| Duffy, SJ | 1 |
| Biegelsen, ES | 1 |
| Holbrook, M | 1 |
| Russell, JD | 1 |
| Gokce, N | 1 |
| Keaney, JF | 1 |
| Vita, JA | 1 |
| Chekanov, VS | 1 |
| Nikolaychik, V | 1 |
| Boucher, F | 1 |
| Pucheu, S | 1 |
| Coudray, C | 1 |
| Favier, A | 1 |
| de Leiris, J | 1 |
| Takemura, G | 1 |
| Onodera, T | 1 |
| Ashraf, M | 1 |
| Mousa, SA | 1 |
| Ritger, RC | 1 |
| Smith, RD | 1 |
| McCord, JM | 2 |
| Liu, XK | 1 |
| Prasad, MR | 1 |
| Engelman, RM | 1 |
| Jones, RM | 1 |
| Das, DK | 1 |
| van Jaarsveld, H | 2 |
| Potgieter, GM | 2 |
| Barnard, SP | 2 |
| Potgieter, S | 1 |
| Lesnefsky, EJ | 1 |
| Repine, JE | 1 |
| Horwitz, LD | 1 |
| Maxwell, MP | 1 |
| Hearse, DJ | 2 |
| Yellon, DM | 1 |
| Sullivan, JL | 2 |
| Ambrosio, G | 1 |
| Zweier, JL | 1 |
| Jacobus, WE | 1 |
| Weisfeldt, ML | 1 |
| Flaherty, JT | 1 |
| Bernard, M | 1 |
| Menasché, P | 2 |
| Piétri, S | 1 |
| Grousset, C | 2 |
| Piwnica, A | 2 |
| Cozzone, PJ | 1 |
| Groenewald, AJ | 1 |
| Vermaak, WJ | 1 |
| Barnard, HC | 1 |
| Russell, WJ | 1 |
| Bernier, M | 1 |
| Manning, AS | 1 |
| Gauduel, Y | 1 |
| Mouas, C | 1 |
| Bolli, R | 1 |
| Patel, BS | 1 |
| Zhu, WX | 1 |
| O'Neill, PG | 1 |
| Hartley, CJ | 1 |
| Charlat, ML | 1 |
| Roberts, R | 1 |
| Badylak, SF | 1 |
| Simmons, A | 1 |
| Turek, J | 1 |
| Babbs, CF | 1 |
| Boffa, GM | 1 |
| Ferrari, R | 1 |
| Dalla Volta, S | 1 |
| Myers, CL | 2 |
| Weiss, SJ | 2 |
| Kirsh, MM | 2 |
| Shepard, BM | 1 |
| Shlafer, M | 2 |
1 review available for deferoxamine and Coronary Disease
| Article | Year |
|---|---|
The iron paradigm of ischemic heart disease.
Topics: Animals; Coronary Disease; Deferoxamine; Female; Humans; Iron; Male; Menopause; Models, Cardiovascul | 1989 |
1 trial available for deferoxamine and Coronary Disease
| Article | Year |
|---|---|
Iron chelation improves endothelial function in patients with coronary artery disease.
Topics: Adult; Blood Flow Velocity; Coronary Disease; Deferoxamine; Endothelium, Vascular; Enzyme Inhibitors | 2001 |
22 other studies available for deferoxamine and Coronary Disease
| Article | Year |
|---|---|
Coronary vascular injury following transient coronary artery occlusion: prevention by pretreatment with deferoxamine, dimethylthiourea and N-2-mercaptoproprionyl glycine.
Topics: Animals; Capillary Permeability; Coronary Disease; Coronary Vessels; Deferoxamine; Dogs; Lipid Perox | 1993 |
Iron contributes to endothelial dysfunction in acute ischemic syndromes.
Topics: Acute Disease; Coronary Circulation; Coronary Disease; Deferoxamine; Endothelial Growth Factors; End | 2002 |
Evidence of cytosolic iron release during post-ischaemic reperfusion of isolated rat hearts. Influence on spin-trapping experiments with DMPO.
Topics: Animals; Coronary Disease; Cyclic N-Oxides; Cytosol; Deferoxamine; Electron Spin Resonance Spectrosc | 1992 |
Quantification of hydroxyl radical and its lack of relevance to myocardial injury during early reperfusion after graded ischemia in rat hearts.
Topics: Animals; Coronary Disease; Deferoxamine; Free Radicals; Gentisates; Heart; Hydroxides; Hydroxybenzoa | 1992 |
Efficacy and safety of deferoxamine conjugated to hydroxyethyl starch.
Topics: Animals; Coronary Disease; Deferoxamine; Edema; Hemodynamics; Hydroxyethyl Starch Derivatives; Lipid | 1992 |
Is iron sufficiency a risk factor in ischemic heart disease?
Topics: Coronary Disease; Deferoxamine; Free Radicals; Humans; Iron; Myocardial Reperfusion Injury; Oxygen; | 1991 |
Role of iron on membrane phospholipid breakdown in ischemic-reperfused rat heart.
Topics: Acylation; Animals; Coronary Disease; Deferoxamine; Fatty Acids, Nonesterified; Heart; Heart Ventric | 1990 |
Improvement of ischemic and postischemic mitochondrial function by deferrioxamine: the role of iron.
Topics: Animals; Coronary Disease; Cytosol; Deferoxamine; In Vitro Techniques; Iron; Male; Mitochondria, Hea | 1990 |
Deferoxamine pretreatment reduces canine infarct size and oxidative injury.
Topics: Animals; Coronary Disease; Coronary Vessels; Deferoxamine; Dogs; Glutathione; Hemodynamics; Male; My | 1990 |
Inability of desferrioxamine to limit tissue injury in the ischaemic and reperfused rabbit heart.
Topics: Animals; Coronary Disease; Deferoxamine; Free Radicals; Hemodynamics; Hydroxides; Hydroxyl Radical; | 1989 |
Improvement of postischemic myocardial function and metabolism induced by administration of deferoxamine at the time of reflow: the role of iron in the pathogenesis of reperfusion injury.
Topics: Adenosine Triphosphate; Animals; Coronary Circulation; Coronary Disease; Deferoxamine; Electron Spin | 1987 |
Cardioplegic arrest superimposed on evolving myocardial ischemia. Improved recovery after inhibition of hydroxyl radical generation by peroxidase or deferoxamine. A 31P nuclear resonance study.
Topics: Animals; Coronary Disease; Deferoxamine; Heart Arrest, Induced; Hydrogen-Ion Concentration; Hydroxid | 1988 |
The effect of allopurinol and deferrioxamine on rat heart mitochondrial oxidative phosphorylation after normothermic ischemic cardiac arrest and of reperfusion.
Topics: Adenosine Diphosphate; Allopurinol; Animals; Coronary Disease; Deferoxamine; Heart Arrest; In Vitro | 1988 |
Inactivation of creatine phosphokinase by superoxide during reperfusion injury.
Topics: Animals; Catalase; Cattle; Coronary Disease; Creatine Kinase; Deferoxamine; Disease Models, Animal; | 1988 |
Sex, iron, and heart disease.
Topics: Coronary Disease; Deferoxamine; Female; Humans; Iron Deficiencies; Male; Sex Factors | 1986 |
Reperfusion-induced arrhythmias and oxygen-derived free radicals. Studies with "anti-free radical" interventions and a free radical-generating system in the isolated perfused rat heart.
Topics: Animals; Arrhythmias, Cardiac; Catalase; Coronary Circulation; Coronary Disease; Deferoxamine; Free | 1986 |
[A new concept of cardioplegic protection in cardiac surgery: iron chelation].
Topics: Animals; Cardiac Surgical Procedures; Cardioplegic Solutions; Coronary Disease; Deferoxamine; Extrac | 1988 |
The iron chelator desferrioxamine attenuates postischemic ventricular dysfunction.
Topics: Animals; Arrhythmias, Cardiac; Coronary Circulation; Coronary Disease; Coronary Vessels; Deferoxamin | 1987 |
Protection from reperfusion injury in the isolated rat heart by postischaemic deferoxamine and oxypurinol administration.
Topics: Animals; Coronary Disease; Creatine Kinase; Deferoxamine; Heart; Male; Microscopy, Electron; Myocard | 1987 |
[Prevention of myocardial damage by oxygen free radicals. Theoretical premises and experimental data].
Topics: Allopurinol; Animals; Antioxidants; Coronary Disease; Deferoxamine; Dogs; Free Radicals; Iron; Manni | 1985 |
Effects of supplementing hypothermic crystalloid cardioplegic solution with catalase, superoxide dismutase, allopurinol, or deferoxamine on functional recovery of globally ischemic and reperfused isolated hearts.
Topics: Allopurinol; Animals; Bicarbonates; Blood Pressure; Calcium Chloride; Catalase; Coronary Circulation | 1986 |
Involvement of hydrogen peroxide and hydroxyl radical in the 'oxygen paradox': reduction of creatine kinase release by catalase, allopurinol or deferoxamine, but not by superoxide dismutase.
Topics: Allopurinol; Animals; Blood Pressure; Catalase; Coronary Circulation; Coronary Disease; Creatine Kin | 1985 |